USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated